Rua Life Sciences Equity 2024

Rua Life Sciences Aktienanalyse

What does Rua Life Sciences do?

Rua Life Sciences PLC is a British company specializing in the development and manufacture of therapeutics and medical devices in the pharmaceutical industry. It was founded in 1999 by Dr. Ahmed Abdullah as Research Chemicals International. In 2007, it was renamed Rua Life Sciences PLC and has been listed on the London Stock Exchange since 2014. The business model of Rua Life Sciences PLC is the research and development of pharmaceuticals. The company invests in the discovery of new active substances and technologies that can be used to treat diseases. In addition, Rua Life Sciences PLC is also involved in the storage and transportation of pharmaceutical products. The product range of Rua Life Sciences PLC includes various areas such as oncology, neurology, ophthalmology, infectious diseases, and cardiovascular diseases. In oncology research, the company works on innovative approaches to the treatment of various types of cancer. This includes the development of drugs to combat breast cancer or lung cancer. In neurology, Rua Life Sciences PLC aims to develop new therapeutics for the treatment of diseases of the nervous system. This includes, among other things, drugs for the relief of Parkinson's or Alzheimer's. In the field of ophthalmology, the company researches drugs for the treatment of eye diseases such as macular degeneration, which leads to vision impairment in older people. This also includes testing new technologies such as the combination of drugs with special apparatus. In infectious diseases research, Rua Life Sciences PLC works on drugs to combat viruses and bacteria that can cause various diseases. This also includes the development of vaccines to counter epidemic outbreaks. Another important area for Rua Life Sciences PLC is research in the field of cardiovascular diseases. The company is working on drugs to treat hypertension, heart attacks, and other cardiovascular diseases. In addition to pharmaceutical products and therapeutics, Rua Life Sciences PLC also offers medical devices. These include blood glucose meters and medical inhalers used in the treatment of respiratory diseases. The company aims to help patients worldwide and save lives. It invests large sums in the research and development of therapeutics and medical devices to improve healthcare for humans and animals. Rua Life Sciences PLC collaborates with leading scientists and biomedical companies and maintains a network of partners around the world. Overall, Rua Life Sciences PLC is a company with a wide product range specializing in the manufacture of pharmaceuticals and medical devices. The company is committed to healing diseases and improving the health of people worldwide. Rua Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Rua Life Sciences's Equity

Rua Life Sciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Rua Life Sciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Rua Life Sciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Rua Life Sciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Rua Life Sciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Rua Life Sciences stock

What is the equity of Rua Life Sciences this year?

Rua Life Sciences has equity of 4.68 M GBP this year.

What was the equity of Rua Life Sciences compared to the previous year?

The equity of Rua Life Sciences has increased/decreased by -28.83% decreased compared to the previous year.

What impact does a high equity have on investors of Rua Life Sciences?

A high equity is advantageous for investors of Rua Life Sciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Rua Life Sciences?

A low equity can be a risk for investors of Rua Life Sciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Rua Life Sciences affect the company?

An increase in equity of Rua Life Sciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Rua Life Sciences affect the company?

A reduction in equity of Rua Life Sciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Rua Life Sciences?

Some factors that can affect the equity of Rua Life Sciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Rua Life Sciences so important for investors?

The equity of Rua Life Sciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Rua Life Sciences take to change the equity?

To change equity, Rua Life Sciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Rua Life Sciences pay?

Over the past 12 months, Rua Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rua Life Sciences is expected to pay a dividend of 0 GBP.

What is the dividend yield of Rua Life Sciences?

The current dividend yield of Rua Life Sciences is .

When does Rua Life Sciences pay dividends?

Rua Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rua Life Sciences?

Rua Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Rua Life Sciences?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rua Life Sciences located?

Rua Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rua Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rua Life Sciences from 8/27/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/27/2024.

When did Rua Life Sciences pay the last dividend?

The last dividend was paid out on 8/27/2024.

What was the dividend of Rua Life Sciences in the year 2023?

In the year 2023, Rua Life Sciences distributed 0 GBP as dividends.

In which currency does Rua Life Sciences pay out the dividend?

The dividends of Rua Life Sciences are distributed in GBP.